Cytori Therapeutics wants to provide patients access to clinical grade regenerative cells thought to promote healing of scarred or injured tissue in the treatment of different medical conditions. Our unique and promising approach provides Adipose-Derived Regenerative Cells (ADRCs, sometimes referred to as stromal vascular fraction cells) and is being evaluated in numerous clinical and preclinical studies around the world.

While we are learning more every day about the exact mechanisms through which ADRCs might promote healing, it is believed that this heterogeneous population of cells influences the local environment via cell-to-cell signaling, immune modulation, and differentiation into other cell types. We are actively pursuing the areas of chronic heart failure, burn care, soft-tissue injury, sports medicine and orthopedics.